The Cancer Genome Atlas (TCGA) LUAD data were included for genomic, transcriptomic, and tumor microenvironment analysis . Low VAF patients experienced significantly longer progression-free survival (PFS) than those of high TP53++ T cells compared with those with high PFS (12.0 vs. 2.1 months) PD-(L)1 monotherapy is independently associated with better efficacy .